Sarepta Therapeutics, Inc.

SRPT·NasdaqGS
Compare
17.44−0.41 (−2.30%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
After hours17.45+0.01 (+0.06%)Oct 12, 7:36 PM EDT

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close17.85
Open17.86
Day range17.3018.14
52-week range14.6824.68
Off day high−3.86%
Off 52-week high−29.34%
Volume3.28M
Avg. volume (3M)2.99M
Market cap1.84B
EPS (TTM)-1.57
Forward P/E7.26
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding105.63M
Short interest—
Earnings dateAug 5, 2026
Analyst target—
Profit margin—

Against its peers

Compare in full ›
SRPT DSGN CAPR IONS TSHA STOK
Market cap 1.84B 682.77M 434.30M 7.26B 1.35B 1.56B
P/E (TTM) — — — — — —
Forward P/E 7.3 -6.7 -5.1 -39.3 -9.0 -6.8
Price/book 1.2 3.4 1.8 16.4 5.6 4.4
Dividend yield — — — — — —
1-year change −18.72% +79.51% +16.52% −35.85% −11.09% −18.46%
Today −2.30% −6.35% −4.60% −3.56% −7.80% −2.38%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All SRPT news ›
@law360·Negative

Gene Therapy Patent Suit Against Sarepta Comes To Close

By Adam Lidgett · October 9, 2026, 8:03 PM EDT REGENXBIO Inc. et al v. Sarepta Therapeutics, Inc., et al. REGENXBIO Inc. v. Sarepta Therapeutics, Inc. Appellate - Federal Circuit 830 Patent Infringement (Fed. Qst.)

markets.businessinsider.com·Positive

Kyverna Therapeutics to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pione... Kyverna Therapeutics to Present at Upcoming Investor Conferences EMERYVILLE, Calif., Sept.…

Markets Daily·Negative

Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwright

Posted by Danessa Lincoln on Oct 6th, 2026 Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating restated by equities researchers at HC Wainwright in a report released on Monday, MarketBeat.com reports. They…

@insidermonkey·

Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics

Toward the end of the October 5 lightning round of Mad Money, a caller asked Jim Cramer about Sarepta Therapeutics, Inc. (NASDAQ:SRPT). He replied: This is a very controversial stock… I want everything to work for people who have this and…

From articles in the 4Search news index.

In the news

19mentions in 30 days
12with it in the headline
Negativesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 19 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.